The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

Table 2 Frontline blinatumomab and inotuzumab combinations in newly diagnosed older B-ALL

	Agent	N	Median age (range), years	Complete remission, %	MRD negativity, %	Overall survival, % (x-year)
Mini-Hyper-CVD-Inotuzumab-blinatumomab [81]	Blinatumomab and inotuzumab	80	68 (60–87)	89	94^∆	47 (5-year)
SWOG-1318 [84]	Blinatumomab	29	73 (66–86)	66	92^∆	37 (3-year)
EWALL-INO [83]	Inotuzumab	115	69 (55–84)	79	73^∆	79 (1-year)
GMALL Bold [144]	Blinatumomab	34	65 (56–76)	76	69^∆∆	89 (1-year)
INITIAL-1 [82]	Inotuzumab	45	64 (56–80)	100	74^∆∆	77 (2-year)

MRD measurable residual disease
^∆MRD negativity assessed by multicolor multiparameter flow cytometry at a sensitivity of 10⁻⁴
^∆∆MRD negativity assessed by RT-PCR at a sensitivity of 10⁻⁴

ISSN: 1756-8722